OR WAIT 15 SECS
The company announced plans to construct a 1.3 million-ft2 integrated manufacturing center in Chengdu, China.
On May 16, 2019, WuXi Biologics, a provider of end-to-end solutions for biologics discovery, development, and manufacturing, announced the construction of a new 1.3 million-ft2 integrated biologics manufacturing center in Chengdu, China.
The manufacturing center will include drug development and commercial manufacturing facilities with an initial bioreactor capacity of 48,000 L. As the company’s 12th drug substances manufacturing facility, the new site is expected to enable more global partners, create more jobs for local talent, stimulate growth of the biologics industry in Chengdu, as well as accelerate the biologics ecosystem in Southwest China, according to the company.
“We are quite excited to commence this new integrated manufacturing center, the largest biologics manufacturing facility in Southwest China,” said Dr. Chris Chen, CEO of WuXi Biologics, in a company press release. “Supported by 205 ongoing biologics projects using WuXi Biologics’ open-access and proprietary platforms as well as our unique manufacturing paradigm of ‘Global Dual Sourcing within WuXi Bio’, we will continue to expand manufacturing capacity, based on our portfolio needs, to provide a robust and premier global supply chain that can enable our partners and benefit patients worldwide.”
Source: WuXi Biologics